Center for Vein Restoration CME Evaluation Form Date: January 30, 2021Topic: CVR VISION 2021 Clinical ConventionSpeakers: Dr. K. Nguyen; Dr. V. Satwah; Dr. N. Morrison; Dr. J. Laredo; Dr. P. Pappas; Dr. M. Gasparis; Dr. Z. Deol; Dr. N. Khilnani; Dr. L. Kelsey; Dr. J. Caprini; Dr. A. Comerota; Dr. S. Vendantham; Dr. K. Gibson; Dr. T. Soto; Dr. G. Lakhanpal; Dr. P. GagneSince attending this presentation, participants should be able to: Understand the etiology, diagnosis, and clinical presentations of Venous Disease Evaluate differential diagnosis in patients with multiple symptoms Learn about current treatment options and disease management To help assess educational needs, evaluate how we are meeting them, improve the CME program, and meet accreditation standards, please complete the following. Question Title * 1. Was it made clear whether or not there was commercial support (sponsorship) for this CME program? Yes No N/A Question Title * 2. What is your first name? Question Title * 3. What is your last name? Question Title * 4. What is your email address? Question Title * 5. Where are you located (City and State)? Question Title * 6. Please list your credentials: Question Title * 7. Did the information provided seem biased or compromised by commercial support? N/A No Yes (please describe) Question Title * 8. Did the information provided seem biased or compromised by commercial support? N/A No Yes (please describe) Question Title * 9. Was disclosure of relevant financial relations provided prior to the presentation? Yes No N/A Question Title * 10. Were your needs addressed? Yes No N/A Question Title * 11. Did this program increase your professional knowledge or skills? Yes No N/A Question Title * 12. What did you learn? Question Title * 13. Will you make any changes in your practice or disease management based on what you learned at this CME activity? N/A No If yes, what will you do differently? Question Title * 14. How do you think this will lead to improved health status for patients? Question Title * 15. What clinical scenario/challenge will this activity help you address better? Question Title * 16. How would you rate the following: Poor Fair Excellent No Opinion Quality of the speaker's presentation Quality of the speaker's presentation Poor Quality of the speaker's presentation Fair Quality of the speaker's presentation Excellent Quality of the speaker's presentation No Opinion Audio-visual quality and function Audio-visual quality and function Poor Audio-visual quality and function Fair Audio-visual quality and function Excellent Audio-visual quality and function No Opinion Platform for broadcasting (Zoom) Platform for broadcasting (Zoom) Poor Platform for broadcasting (Zoom) Fair Platform for broadcasting (Zoom) Excellent Platform for broadcasting (Zoom) No Opinion Platform for registration (EventBrite) Platform for registration (EventBrite) Poor Platform for registration (EventBrite) Fair Platform for registration (EventBrite) Excellent Platform for registration (EventBrite) No Opinion Question Title * 17. Patients who have had iliofemoral DVT treated with anticoagulation Are more than 2X as likely to have severe post-thrombotic morbidity as patients with femoral-popliteal or calf vein thrombosis. Often have the thrombus evolve to a collagen based chronic venous obstruction. As part of the ATTRACT Trial had significantly worse Post-Thrombotic Syndrome and worse QOL than those treated with Pharmaco-mechanical Catheter Directed Thrombolysis All of the above are correct A and C are correct Question Title * 18. Evidence supports that saphenous ablation reduces the risk of progression to venous ulceration in patients with: Varicose veins Venous edema Corona phlebectatica Lipodermatosclerosis None of the above Question Title * 19. Early intervention for superficial reflux in patients with venous leg ulcers Reduces ulcer recurrence Is not cost effective Improves time free ulcer Has no effect on ulcer healing rates Question Title * 20. Which of the following is NOT a design feature of the C-TRACT Clinical Trial? Both off-label stents and FDA-approved venous stents are allowed in the trial Venoactive medications may use used in study patients. Randomized controlled trial Patients and providers are blinded to treatment arm Outcome assessors are blinded to treatment arm Question Title * 21. Please this space to list any additional comments you have about the presenter, material, or platform. Done